| Previous Close | 65.990 |
| Open | 66.020 |
| Bid | 65.850 x 2700 |
| Ask | 65.860 x 900 |
| Day's Range | 65.680 - 66.160 |
| 52 Week Range | 58.290 - 66.800 |
| Volume | 2,327,252 |
| Avg. Volume | 8,067,317 |
| Market Cap | 179.61B |
| Beta | 0.94 |
| PE Ratio (TTM) | 35.66 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | 1.88 (2.84%) |
| Ex-Dividend Date | 2017-09-14 |
| 1y Target Est | N/A |
- InvestorPlace•yesterday
Buy Bristol-Myers Squibb Co (BMY) Stock With No Fear
Bristol-Myers Squibb Co (NYSE:BMY) stock has had a tumultuous 12-month period. In January, it fell 20% but luckily for the bulls it recovered all of it within five weeks. Since then and after several +/-8% moves, BMY is up 12% in 52 weeks which is decent but still underwhelming relative to the iShares Nasdaq Biotechnology Index (ETF) (NASDAQ:IBB) as a whole.Source: A 4 via Flickr
- Motley Fool•yesterday
The Top Cancer Immunotherapies Expected to Reach $1 Billion in Sales in 2017
These next-generation medicines are quickly becoming the foundation for advanced cancer treatments.
